These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 6603904

  • 1. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
    Cass CE, Selner M, Phillips JR.
    Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
    [Abstract] [Full Text] [Related]

  • 2. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW, Cheng YC, Schabel FM, Montgomery JA.
    Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE, Au-Yeung TH.
    Cancer Res; 1976 Apr; 36(4):1486-91. PubMed ID: 944095
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    White EL, Shaddix SC, Brockman RW, Bennett LL.
    Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
    [Abstract] [Full Text] [Related]

  • 5. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.
    Cass CE, Tan TH, Selner M.
    Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin.
    Cass CE, Selner M, Tan TH, Muhs WH, Robins MJ.
    Cancer Treat Rep; 1982 Feb; 66(2):317-26. PubMed ID: 6976834
    [Abstract] [Full Text] [Related]

  • 7. Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin.
    LePage GA, Worth LS, Kimball AP.
    Cancer Res; 1976 Apr; 36(4):1481-5. PubMed ID: 946595
    [Abstract] [Full Text] [Related]

  • 8. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
    Barrueco JR, Jacobsen DM, Chang CH, Brockman RW, Sirotnak FM.
    Cancer Res; 1987 Feb 01; 47(3):700-6. PubMed ID: 3802076
    [Abstract] [Full Text] [Related]

  • 9. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
    Matsushita T, Ryu EK, Hong CI, MacCoss M.
    Cancer Res; 1981 Jul 01; 41(7):2707-13. PubMed ID: 7248939
    [Abstract] [Full Text] [Related]

  • 10. Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity.
    Kufe DW, Major PP, Munroe D, Egan M, Herrick D.
    Cancer Res; 1983 May 01; 43(5):2000-4. PubMed ID: 6831429
    [Abstract] [Full Text] [Related]

  • 11. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM, Rustum YM.
    Cancer Res; 1985 Dec 01; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [Abstract] [Full Text] [Related]

  • 12. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases.
    Verhoef V, Sarup J, Fridland A.
    Cancer Res; 1981 Nov 01; 41(11 Pt 1):4478-83. PubMed ID: 6272978
    [Abstract] [Full Text] [Related]

  • 13. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.
    Walsh CT, Craig RW, Agarwal RP.
    Cancer Res; 1980 Sep 01; 40(9):3286-92. PubMed ID: 7427943
    [Abstract] [Full Text] [Related]

  • 14. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
    Plunkett W, Benjamin RS, Keating MJ, Freireich EJ.
    Cancer Res; 1982 May 01; 42(5):2092-6. PubMed ID: 6175407
    [Abstract] [Full Text] [Related]

  • 15. Resistance to 9-beta-D-arabinofuranosyladenine in murine tumor cells.
    LePage GA.
    Cancer Res; 1978 Aug 01; 38(8):2314-6. PubMed ID: 580902
    [Abstract] [Full Text] [Related]

  • 16. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
    Plunkett W, Cohen SS.
    Cancer Res; 1975 Jun 01; 35(6):1547-54. PubMed ID: 1079475
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines.
    Orr RM, Talbot DC, Aherne WG, Fisher TC, Serafinowski P, Harrap KR.
    Clin Cancer Res; 1995 Apr 01; 1(4):391-8. PubMed ID: 9815996
    [Abstract] [Full Text] [Related]

  • 19. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
    Sato A, Montgomery JA, Cory JG.
    Cancer Res; 1984 Aug 01; 44(8):3286-90. PubMed ID: 6611198
    [Abstract] [Full Text] [Related]

  • 20. Selection of 9-beta-D-arabinofuranosyladenine-resistant human T-lymphoblasts with altered ribonucleotide reductase activity.
    Fridland A.
    Cancer Res; 1984 Oct 01; 44(10):4328-32. PubMed ID: 6380707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.